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Abstract
Faecal microbiota transplantation is effective for treating recurrent forms of 
Clostridium difficile infection and its use in this indication is recommended in the most 
recent European and North American guidelines. In this context, faecal microbiota 
transplantation is beginning to be performed in France in clinical practice, while the 
rules governing this procedure have been defined in France only for clinical trials. To
unify, secure, and evaluate practice in this field in France, the French Group of 
Faecal microbiota Transplantation (FGFT) was created in October 2014 with the 
support of the French National Society of Gastroenterology, the French Infectious 
Disease Society, and the National Academy of Pharmacy. We present here the 
deliberations of this group regarding the use of faecal microbiota transplantation for 
recurrent Clostridium difficile infection. The issues addressed are the indications, 
therapeutic sequence, delivery procedures, donor selection, methods and conditions 
of specimen preparation, and traceability.
Keywords : Clostridium difficile; faecal microbiota transplantation; recommendations
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1. Introduction
Many concordant studies, including a recently published randomised trial 1, have 
shown that faecal microbiota transplantation (FMT) is effectivef or treating recurrent
forms of Clostridium difficile infection (CDI). The use of FMT in this indication is 
recommended in the most recent European 2 and North American 3 guidelines.
In this context, FMT is beginning to be performed in France in clinical practice, while 
the rules governing FMT have been defined in France only for clinical trials (ANSM
March 2014: http://ansm.sante.fr/S-informer/Points-d-information-Points-d-
information/La-transplantation-de-microbiote-faecal-et-son-encadrement-dans-les-
essais-cliniques-Point-d-information). The conditions under which FMT is performed 
in France are variable and not always optimal, in particular regarding the selection of 
donors.
Therefore, it appears necessary to provide recommendations to secure and clarify
practice in this field in France. To address these issues, the French Group of Faecal
microbiota Transplantation (FGFT) was created in October 2014 with the support of 
the French National Society of Gastroenterology (SNFGE). This initiative was 
received very favourably by many players in the field in France and also received the 
support of the French Society of Infectious Disease (SPILF) and the National 
Academy of Pharmacy.
Physicians, pharmacists and biologists actively involved in FMT in France gathered in 
December 2014 to develop recommendations to regulate the use of this procedure in 
clinical practice, especially in cases of multiple recurrent CDI (a recognised indication 
with international consensus). Indeed, recurrent CDI is frequent and increasing; it
represents a real therapeutic problem with significant morbidity (repeated 
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hospitalisations, sick leave etc.) and substantial mortality. Patients with CDI are 2.5 
times more likely to die within 30 days of infection compared to uninfected patients, 
regardless of their age and co-morbidities 4. This mortality rate could be greater in 
patients with the recurrent form compared to those with a single episode 5. Failure to 
perform FMT in France within a regulatory framework and according to standard, 
achievable and secure procedures represents a loss of opportunity for patients in the 
absence of alternative treatment with similar efficacy. Given the logistical and 
practical issues of the procedure, particularly with regard to donor testing, it is critical 
to create reference centres in France and standardised procedures.
After first contact in October 2014, a panel of expert gastroenterologists and 
infectious diseases specialists, microbiologists, and pharmacists was established to 
prepare a position statement on faecal transplantation. The panel met on December 
10th, 2014 in Paris to define the timeline and milestones of the document. Regular 
conference calls followed and web-based data exchange were initiated. The following 
text represents the synthesis of the deliberations of the FGFT. It is based on the 
practical experience of each participant, the advice of expert microbiologists, the 
upstream work by the National Academy of Pharmacy, the ANSM and the analysis of 
practices in Europe and the United States. The issues addressed are the indications, 
therapeutic sequence, delivery procedures, donor selection, methods and conditions 
of specimen preparation, and traceability.
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2. INDICATIONS
In line with the recommendations of the European Society of Clinical Microbiology 
and Infectious Diseases (ESCMID) 2014 2, the FGFT finds FMT indicated in multiple 
recurrent CDI (defined as more than one recurrence). FMT considered in the context 
of recurrent CDI can only be performed after failure of standard well-conducted 
treatment with vancomycin or fidaxomicin.
With the current state of knowledge, there are no contraindications for FMT. In 
particular, recent data reported good safety, even in immunocompromised patients 6.
3. THERAPEUTIC SEQUENCE
The treatment sequence involves three steps: (i) oral antibiotic therapy with 
vancomycin, (ii) bowel preparation, and (iii) the delivery of the faecal suspension itself 
(Figure 1).
In agreement with the European guidelines, we recommend antibiotic treatment with 
vancomycin given orally for a minimum of four days before FMT (125 to 500 mg four 
times daily). Interruption of antibiotics for 24 to 72 h before FMT is possible but not 
mandatory. Studies are currently underway to evaluate the use of fidaxomicin as a
pre-treatment.
It is recommended to perform bowel preparation the day before FMT by 
administering 4 L of a bowel cleansing solution containing macrogol (polyethylene 
glycol [PEG]) 3350 cc or 4000 cc with electrolytes.
After receiving the relevant information, the patient must sign a consent form 
mentioning the theoretical risks of the procedure, including the risk of pathogen 
transmission. Consent must be signed in triplicate: one for the recipient, one for the 
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patient's medical record and one for the archives (see the section below on 
"Traceability").
It is recommended to monitor the recipient at least 24 h after the FMT procedure.
Performing FMT does not change overall patient monitoring following CDI treatment.
The literature indicates that a second FMT may be necessary in the case of failure, or 
recurrence after a first attempt 1. This strategy is effective and recommended.
4. DELIVERY PROCEDURES
Three routes of delivery are possible: retention enema, during colonoscopy, or using 
a naso-duodenal tube.
4.1 Retention enema
Faecal preparation (up to 500 mL) should be placed in a disposable enema bag. The 
preparation is dispensed by the hospital pharmacy in a disposable enema bag. The 
pre-lubricated cannula is inserted as far as possible according to the patient's 
tolerance. The administration is then performed by a nurse as usual for an enema. 
The patient must retain this enema as long as possible (minimum 2 h). For 
convenience, the patient should remain lying down after insertion.
4.2 Colonoscopy
Faecal preparation (about 300 mL) is provided by the hospital pharmacy in 50- to 60-
mL syringes. Colonoscopy should be performed under low pressure. Ideally, the
faecal preparation should be administered upstream of the splenic flexure. 
4.3 Naso-duodenal tube
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The procedure must be carried out in the morning on an empty stomach in a patient 
who received treatment with proton pump inhibitors (esomeprazole 20 mg or 
omeprazole 40 mg) the night before and 2–3 h before FMT. Before FMT, the tube
must be placed at least in the duodenum and if possible in the proximal jejunum. The 
correct tube positioning should be confirmed by X-ray.
Faecal preparation (250–500 mL) is provided by the hospital pharmacy in a 50- to 60-
mL syringe (or in an enteral nutrition bag). The preparation should be administered at 
a rate of 50 mL over 2 min. If the use of a volume greater than 250 mL is intended, a 
10- to 15-minute pause is recommended following administration of the first 250 mL.
Patients are allowed to drink during the procedure. After administration of the faecal
preparation, the naso-duodenal tube will be rinsed with tap water and left in place for 
30 min before removal. Patients are then monitored for 2 h.
The naso-duodenal route is not recommended in patients at risk of vomiting or 
regurgitation, because of the risk of aspiration pneumonia.
5. DONOR SELECTION
Although we propose absolute and relative criteria for donor selection, the severity of 
the patient's disease remains the prevailing factor; the rigorous application of these 
criteria remains at the discretion of the multidisciplinary team responsible for the 
implementation of FMT (doctor, pharmacist, biologist), on a case-by-case basis, 
depending on the urgency of the situation and on the assessment of the individual 
risk-benefit ratio.
5.1 General donor pathway
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The donor must first meet criteria of the pre-selection questionnaire, to exclude any 
contraindications (Table 1). The donor must then undergo physical examination by a 
physician, including the examination of the anal margin to search for lesions 
attributable to human papillomavirus (HPV) or herpes simplex virus (HSV). Blood and 
faecal testing is then performed (Tables 2 and 3) to exclude infection with
transmissible agents. FMT should be performed within 21 days of the screening. On 
the day of FMT, the donor must answer a last questionnaire (Table 4) to ensure the 
absence of inter-current events since the initial clinical and laboratory screening that 
may represent a contraindication to donation.
The donor stools must be produced on the day of FMT, and stored at 4°C until 
preparation. The maximum interval between donor stool emission and recipient
delivery is 6 h. A macrogol- or lactulose-based osmotic laxative can be administered 
to the donor the evening preceding FMT, to facilitate stools emission.
5.2 Pre-selection questionnaire 
Potential donors should be evaluated thoroughly, through a questionnaire and a
medical examination, to reduce the likelihood of transmission of pathogens 
(infectious and others).
The existing questionnaires provided for the screening of blood donors
(http://www.dondusang.net/rewrite/nocache/site/37/etablissement-francais-du-
sang.htm?idRubrique=756) represents a solid basis to limit the risk of infection. 
However, additional measures should be considered to adapt the questionnaire to 
stool donation. In particular, it is important to collect the information specified in Table 
1, in addition to the information required for blood donation.
Page 10 of 28
Ac
ce
pte
d M
an
us
cri
pt
After analysing the information gathered in the pre-selection questionnaire and during 
the interview that follows, the clinician decides whether the candidate can be 
selected to perform the biological screening.
This screening interview is also an opportunity to educate potential donors about the 
importance of limiting contamination before donation by providing recommendations 
in this regard (including food, travel, high-risk behaviours).
Considering the possible contamination window between the screening date and the 
actual FMT date, a second questionnaire and a medical interview are performed on 
the day of the donation. All items listed in Table 4 must be collected. After the second 
medical interview, according to the results of the biological screening and at the 
discretion of the investigator leading the interview, the donor can definitively selected 
for donation.
5.3 Standard donor screening 
Blood tests should be performed in the pre-selected donor and must include: fasting 
glycaemia, creatinine, liver function tests (aspartate aminotrasnferase , alanine 
aminotrasnferase, gamma-glutmayl transpeptidase, alkaline phospatase, bilirubin), 
C-reactive protein, compl te blood count, coagulation tests.
5.4 Screening for infectious agents 
In FMT, the screening tests for communicable disease listed in Tables 2 and 3 should 
be performed in the donor. This list is not static and must be regularly reassessed on 
the basis of the data available in the medical literature. It was elaborated taking into 
account the risk of transmission of infectious agents, the means available to detect 
these agents on solid stools from asymptomatic individuals, and the potential severity 
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of a hypothetical transmission to the recipient. The rationale for these tests is detailed 
in Appendix B (Supplementary Methods).
The prevention of transmission of infectious agents from a donor to a patient 
receiving FMT is based on history and microbiological testing.
None of the procedures fully guarantees against the possible transmission of a 
pathogen present in very small quantities and/or excreted intermittently. The 
likelihood of such a residual presence is impossible to quantify, but is considered low 
and without serious consequences at the present state of knowledge. This is 
mentioned in the informed consent for the recipient.
Characteristics of the ideal donor profile include: age 18–65 years, BMI <30, no
chronic disease, no long-term medical treatment, no travel abroad (in tropical 
countries at risk of infection) in the 3 months before donation, no hospitalisations
abroad (in tropical countries with a risk of infection) in the 12 months before donation, 
normal macroscopic appearance of stools, and negative screening for infectious 
agents.
5.5 Optimal timing for each rocedure step (Figure 2)
5.5.1 Between screening and donation
Using fresh stools for FMT, the faeces screened for pathogens are not those actually 
administered to the recipient.
The time between screening and donation must match the turnaround time for test 
results and be as short as possible without exceeding 21 days, to minimise the risk of 
contamination during this critical period.
Ideally the use of frozen donor faeces would allow microbiological testing directly on 
the material administered to the recipient, and would thus minimise the risk of 
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transmission of infectious agents. However, no validated protocol is available 
regarding preparation and storage of FMT from frozen stools, although some data on 
effectiveness exist 7-10.
5.5.2 Between donation and transplantation
Once prepared, the faecal suspension should be administered within 6 h of the bowel 
movement.
5.6 Anonymous vs. directed donation
For the indication of recurrent C. difficile infection, there is currently no scientific 
argument in favour of an anonymous donation versus a directed donation (from 
household contacts or relatives).
Although a directed stool donation may be possibly easier for the recipient to accept
psychologically, two issues must be considered:
First, the veracity of the answers provided by the donor could be compromised by the 
fear of not being selected for the donation. The safety of the donation is based partly 
on the transparency of information provided by the donor during the medical interview 
and on the completeness of the questionnaire.
Second, one should consider the potential difficulty of communicating the exclusion 
of a close relative, and its consequences.
Conversely, one can also consider that if donor and recipient are close relatives or 
husband and wife, they largely share the same exposure to infectious agents. The 
risk of microbiological transmission could therefore be reduced.
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Consequently, no specific recommendation is made and the donor can be the 
spouse, a family member or have no relationship with the recipient. In all cases, the 
same screening tests should be carried out.
5.6 Number of donors and recipients
5.6.1 One donor for multiple recipients
The donation from one donor can be intended for different recipients. At the current 
state of knowledge, there are no data available that allow the identification of a 
preferred microbiota in healthy subjects and there is no argument in favour of a single 
donor directed to a single recipient.
The choice of an anonymous donor donating to multiple recipients would provide  
standardised material and alleviate the logistical constraints associated with the 
selection of donors.
5.6.2 Multiple donors for one recipient
Similarly, there is no argument in favour of a unique donation over “pooled” donations 
(i.e., a mixture of stools from several donors to prepare a single specimen). However, 
using "pooled" donations further complicates the problem of traceability.
6. PREPARATION OF FMT MATERIAL
6.1 Setting for preparation of faecal suspension
The pharmaceutical preparation status in France11 requires the preparation of faeces 
for the FMT to be carried out under the responsibility of the institution pharmacist.
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For health facilities whose pharmacy lacks the technical means and/or appropriate 
equipment or local logistical requirements, a subcontracting agreement can be 
signed with another pharmacy.
If a medical biology laboratory within the institution has the resources required to 
process stool, a subcontracting agreement can be made by the pharmacist, provided 
that the latter conducts the pharmaceutical validation at preparation release and 
dispensation.
6.2 Organisation for preparing faecal microbiota
Standardisation of the preparation method is required.
6.2.1 Stool collection
The stools are collected in a disposable container with a wide opening and a tight lid. 
The sample for FMT must not contain urine.
Given the short time (less than 6 h) between the emission of stools and delivery of 
the preparation, a coordinated mobilisation of the pharmaceutical team (treatment of 
FMT sample), the biological team (collection of blood and faecal test results), and the 
clinical team (delivery of FMT preparation to the recipient) is needed.
6.2.2 Dedicated room and equipment
Preparation of stool is carried out in a dedicated room. It is performed in a biosafety 
cabinet to avoid the risk of cross-contamination and ensure the protection of 
personnel.
Operators should be protected by wearing a cassock, a cap, a disposable protective 
mask, protective glasses and disposable gloves.
All preparation steps are performed at room temperature.
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6.2.3 Dilution
The stools are diluted in sterile NaCl 0.9% to meet the isotonicity of the sample 
(sterile NaCl 0.9% can be refrigerated to minimise organoleptic imbalance).
A minimum of 50 g up to a maximum of 150 g of stool can be used.
Homogenisation of the dilution is carried out using a dedicated materials in which
elements in contact with faeces are autoclavable or disposable.
The dilution must result in a suspension with a "liquid slurry" consistency and a final 
volume between 200 and 500 mL.
6.2.4 Filtration
The preparation is filtered through sterile gauze compresses placed on an autoclave-
ready or disposable funnel to remove large particles such as undigested food debris 
that may block the delivery systems.
6.2.5 Packaging
For delivery by naso-duodenal tube or colonoscopy, packaging is carried out in 50 to 
60 mL syringes (3–10 syringes). When delivered via naso-duodenal tube, the faecal
suspension can also be packaged in an enteral nutrition bag, opaque if possible, for 
better acceptability.
For delivery via enema, the packaging is a disposable enema bag (500 mL) with an
incorporated lubricated tube.
The preparation is labelled as a pharmaceutical preparation and reports the 
administration route (rectal or duodenal) and formulation batch number. A welded 
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labelled polyethylene overpack is used to facilitate transport. Transportation to the 
ward performing delivery is preferably carried out in a container at 2 °C to 8 °C.
7. TRACEABILITY
It is essential to ensure rigorous traceability of the FMT. For this purpose, biological 
samples from the donor should be stored and a batch file must be created and 
archived.
7.1. Biological samples
For each FMT, two samples from the donor are stored at -80 °C:
Stool collection: 1–2 g of stool collected at the time of the donation, in a 
polypropylene tube
Sample collection: 1–5 mL of preparation administered to the recipient in a 
polypropylene tube
7.2 Batch record data
For each FMT, the batch record must contain:
Biological data: Stool specimen validation, blood collection validation
Relevant paperwork: First donor screening questionnaire, second donor screening 
questionnaire on the day of donation, informed consent of the recipient
Pharmaceutical data: origin of stools (donor identification, date and time of the 
donation), all technical data on preparation (manufacturing records, inspection 
sheet).
Samples must be stored under conditions of optimal stability at -80°C for at least 3 
years for each delivered sample (required to monitor possible adverse effects) and at 
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least 5 years for stool (time to satisfy additional epidemiological and microbiota
studies).
Recording of clinically relevant events occurring within 2 weeks of the donation is 
highly recommended for both donor and recipient (i.e., any infectious disease in the 
donor).
Finally, the creation of a national registry is strongly recommended, to record the 
effectiveness of the procedure and clinical events in the short and long term in both 
donors and recipients.
Conflict of interest: none declared
Appendix A: French Group of Faecal Transplantation (FGFT)
Laurent Alric (Toulouse), Jean-Paul Aucouturier (Reims), Aurelien Amiot (Créteil), 
Frederic Barbut (Paris), Rui Batista (Paris), Laurent Beaugerie (Paris), Pascale 
Bemer (Nantes), Robert Benamouzig (Bobigny), Nicolas Benech (Lyon), Claire 
Billioud (Lyon), Gille Boschetti (Lyon), Pierre Bourlioux (Paris), Nour Boubaddi 
(Brive), Guillaume Bouguen (Rennes), Arnaud Bourreille (Nantes), Franck Carbonnel 
(Kremlin Bicêtre), Elodie Cesbron-Metivier (Angers), François Chast (Paris), Benoit 
Coffin (Colombes), Anne Collignon (Paris), Michael Collins (Kremlin Bicêtre), Thierry 
Davion (Lens), Henri Duboc (Colombes), Philippe Ducrotte (Rouen), Thibaut Fraisse 
(Ales), Tatiana Galperine (Lille), Benoit Guery (Lille), Marielle Guillet (Lyon), B. 
Heyman (Amiens), Anne-Christine Joly (Paris), Francisca Joly (Clichy), Nathalie 
Kapel (Paris), Alexis Mosca (Paris), Biba Nebbad (Créteil), Gabriel Perlemuter 
(Clamart), Jean-Marie Reimund (Strasbourg), Matthieu Revest (Rennes), Julien 
Scanzi (Clermont-Ferrand), Philippe Seksik (Paris), Iradj Sobhani (Créteil), Harry 
Page 18 of 28
Ac
ce
pte
d M
an
us
cri
pt
Sokol (Paris), Stephane Schneider (Nice), Caroline Trang (Nantes), Stephanie 
Viennot (Caen), Maurice Viala (Nîmes), Frank Zerbib (Bordeaux).
Page 19 of 28
Ac
ce
pte
d M
an
us
cri
pt
References
1. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces 
for recurrent Clostridium difficile. N Engl J Med 2013;368:407-15.
2. Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology 
and Infectious Diseases: update of the treatment guidance document for Clostridium 
difficile infection. Clin Microbiol Infect 2014;20 Suppl 2:1-26.
3. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, 
and prevention of Clostridium difficile infections. Am J Gastroenterol 2013;108:478-
98; quiz 99.
4. Hensgens MP, Goorhuis A, Dekkers OM, et al. All-cause and disease-specific 
mortality in hospitalized patients with Clostridium difficile infection: a multicenter 
cohort study. Clin Infect Dis 2013;56:1108-16.
5. Taori SK, Wroe A, Poxton IR. Clostridium difficile infections in South East 
Scotland: mortality and recurrence in a region without PCR ribotype 027. J Med 
Microbiol 2013;62:1468-77.
6. Kelly CR, Ihunnah C, Fischer M, et al. Faecal microbiota transplant for 
treatment of Clostridium difficile infection in immunocompromised patients. Am J 
Gastroenterol 2014;109:1065-71.
7. Hamilton MJ, Weingarden AR, Sadowsky MJ, et al. Standardized frozen 
preparation for transplantation of faecal microbiota for recurrent Clostridium difficile 
infection. Am J Gastroenterol 2010;107:761-7.
8. Hamilton MJ, Weingarden AR, Unno T, et al. High-throughput DNA sequence 
analysis reveals stable engraftment of gut microbiota following transplantation of 
previously frozen faecal bacteria. Gut Microbes 2013;4:125-35.
Page 20 of 28
Ac
ce
pte
d M
an
us
cri
pt
9. Youngster I, Russell GH, Pindar C, et al. Oral, capsulized, frozen faecal
microbiota transplantation for relapsing Clostridium difficile infection. JAMA 
2014;312:1772-8.
10. Youngster I, Sauk J, Pindar C, et al. Faecal microbiota transplant for relapsing 
Clostridium difficile infection using a frozen inoculum from unrelated donors: a 
randomized, open-label, controlled pilot study. Clin Infect Dis 2014;58:1515-22.
11. Megerlin F, Fouassier E, Lopert R, et al. Faecal microbiota transplantation: a 
sui generis biological drug, not a tissue. Ann Pharm Fr 2014;72:217-20.
12. Schwartz M, Gluck M, Koon S. Norovirus gastroenteritis after faecal microbiota 
transplantation for treatment of Clostridium difficile infection despite asymptomatic 
donors and lack of sick contacts. Am J Gastroenterol 2013;108:1367.
13. Kump PK, Krause R, Allerberger F, et al. Faecal microbiota transplantation –
the Austrian approach. Clin Microbiol Infect 2014;20:1106-11.
14. Kump PK, Krause R, Steininger C, et al. [Recommendations for the use of 
faecal microbiota transplantation "stool transplantation": consensus of the Austrian 
Society of Gastroenterology and Hepatology (OGGH) in cooperation with the 
Austrian Society of Infectious Diseases and Tropical Medicine]. Z Gastroenterol 
2014;52:1485-92.
Page 21 of 28
Ac
ce
pte
d M
an
us
cri
pt
Figure Legends
Figure 1: Faecal microbiota transplantation: treatment sequence
PEG, polyethylene glycol; FMT faecal microbiota transplantation
Figure 2: Timeline for faecal microbiota transplantation donor screening, stool 
donation and sample preparation
FMT faecal microbiota transplantation
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Table 1 : Screening Questionnaire (specific items for stool donation)
INFORMATION EXCLUSION CRITERIA SELECTION CRITERIA WITH PERSONAL 
ASSESSMENT
Co-morbidities Digestive disorders (acute or 
chronic diarrhea) within 3 months 
prior to donation
Known chronic disease
History of typhoid fever
Donors with family history of:
- Inflammatory bowel disease (relation)
- Autoimmune diseases (relation)
- Colon cancer (relation and age at onset)
Donors with personal history of 
uncomplicated hypertension or 
hypercholesterolemia 
Drug Treatment Donor under long term medical 
treatment. 1
Antibiotic intake within 3 months 1
Treatment of uncomplicated hypertension 
or hypercholesterolemia
Travels Living in tropical areas during the 
3 months prior to donation
Long-term residence in tropical 
areas
Hospitalizations abroad longer
than 24 hours in the 12 months 
prior to donation (including 
members of the donor's 
entourage)2
Game consumption (trichinosis screening 
mandatory)
Age Minor donor3 Aged donor (>65 years)4
Weight status Non limiting Donor with Body mass index>305
1  For reasons of efficiency: the microbiota may be altered 
2 To avoid multiresistant bacteria colonisation
3 In the absence of scientific evidence, minors should not be included, applying the general principles 
governing the donation and use of elements and products of the human body (art. L. 1241-2 and L. 
1121-7 of the public health code)
4 In the elderly, the microbiota may be modified and the risk of co-morbidities is more important
5 Obese subjects have a modified microbiota and preclinical results have shown that it is possible to 
transfer disorders such as obesity and diabetes through the microbiota
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Table 2 :  List of infectious agents to screen in donors
Blood (serology) Stools
Ba
ct
er
ia
Treponema pallidum (TPHA, VDRL)
Clostridium difficile
Standard stool culture : Salmonella, 
Yersinia, Shigella, Campylobacter
Multiresistant bacteria  1
Vi
ru
s1
HIV
HTLV
HAV, HBV, HCV, HEV
CMV 3 
Norovirus2
Rotavirus2 (only if the donor is a child 
<8 years)
Pa
ra
si
te
s
Strongyloïdes stercoralis 4
Ameobosis 4
Trichinella sp. 5
Strongyloïdes stercoralis
Cryptosporidium sp.
(immunocompromised patients). 6
Cyclospora sp. 6
Entamoeba histolytica 6,7
Giardia intestinalis 6
Isospora sp. 6
Microsporidia 6
1 Swab on stool samples, search for glycopeptide resistant enterococci (GRE), Extended spectrum 
beta-lactamase producing bacteria and Carbapenemase producing enterobacteria
2 stool is examined for viruses in using mol cular biology tests (PCR)
3 Only to exclude sero-discordance with the recipient
4 Serology if reported travel to high-risk areas
5 reported game consumption only
6 Parasitological examination of stool on three different samples.
7 In case of travel to amoeba endemic areas, PCR for E. histolityca is recommended
TPHA, Treponema Pallidum Hemagglutinations Assay; VDRL, Veneral Disease Research Laboratory; 
HIV, Human Immunodeficiency Virus; HTLV, Human t-cell Leukemia Virus; HAV, Hepatitis A Virus;
HBV, Hepatitis B Virus; HCV, Hepatitis C Virus;  HEV, Hepatitis E Virus; CMV, Cytomegalovirus
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Table 3: Bacterial screening methods in healthy donor stool
Bacteria Recommended method (on stool)1
Carbapenemase-producing bacteria 
Extended spectrum beta-lactamase 
producing bacteria
Culture on two different specific media (or validated molecular 
method)
Campylobacter sp. Culture on specific medium
C. difficile Culture on specific medium allowing spore germination (or 
validated molecular method)
Salmonella sp. Culture on specific medium after enrichment 
Shigella sp. Culture on specific medium
Yersinia  sp. Culture on Cefsulodin-Irgasan-Novobiocin medium
1Each procedure uses commercialized material and should be performed following the 
manufacturer's recommendations. The techniques for identifying pathogens or antibiotic-resistant 
bacteria mentioned below should take into account the specificity of isolation on formed stools of 
asymptomatic donors.
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Table 4 : Screening questionnaire / Events since the screening visit
EXCLUSION CRITERIA
SELECTION on the basis of individual 
assessment
Diarrhoea (> 3 loose or liquid stools/day) 
Situations at risk of contamination :
- Travel in tropical areas
- Contact with human blood (sting, wound, showing, 
piercing*, tattoo*)
- Sexual high-risk behaviour
- Presence of anal lesions caused by Human 
papilloma virus or Herpes Simplex Virus 
Specific events to be investigated:
Medical consultation (reason)
Contracted disease (type, date and duration)
Medication (type,  date of last intake)
Travel abroad 
Diarrhoea (> 3 loose or liquid stools/day)
among members of the entourage (including 
children) within 4 weeks of donation.
*if not performed in France 
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